HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

parsatuzumab

for treatment of advanced or metastatic breast cancer

Also Known As:

MEGF-0444A; MEGF0444A; RG-741; RG-7414; RG7414

Networked: 3 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Anderson, Maria: 3 articles (01/2018 - 01/2017)
2.	Chang, Ilsung: 3 articles (01/2018 - 01/2017)
3.	Chen, Daniel: 3 articles (01/2018 - 01/2017)
4.	Hegde, Priti: 3 articles (01/2018 - 01/2017)
5.	McCall, Bruce: 3 articles (01/2018 - 01/2017)
6.	Rhee, Ina: 3 articles (01/2018 - 01/2017)
7.	Wakshull, Eric: 3 articles (01/2018 - 01/2017)
8.	Ye, Weilan: 3 articles (01/2018 - 01/2017)
9.	Argiles, Guillem: 2 articles (10/2017 - 01/2017)
10.	Braiteh, Fadi: 2 articles (10/2017 - 01/2017)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 10/01/2017 - "Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer." 01/01/2017 - "Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer." 01/01/2017 - "This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2018 - "This phase II trial evaluated the efficacy of the anti-EGFL7 antibody, parsatuzumab, in combination with bevacizumab plus platinum-based therapy for advanced or recurrent nonsquamous non-small cell lung cancer (NS-NSCLC). " 01/01/2018 - "Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer."
3.	Disease Progression 01/01/2017 - "One-hundred twenty-seven patients were randomly assigned to parsatuzumab, 400 mg, or placebo, in combination with mFOLFOX6 plus bevacizumab, 5 mg/kg. Treatment cycles were repeated every 2 weeks until disease progression or unacceptable toxicity for a maximum of 24 months, with the exception of oxaliplatin, which was administered for up to 8 cycles. "

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	parsatuzumab
3.	Platinum
4.	Immunoglobulin G (IgG)
5.	Fluorouracil (Carac)
6.	Leucovorin (Folinic Acid)
7.	Monoclonal Antibodies
8.	Oxaliplatin (Eloxatin)
9.	Paclitaxel (Taxol)
10.	Carboplatin (JM8)

Related Therapies and Procedures

1.	Therapeutics